Deuterated nintedanib

N/A

Report date: 2025/02/28 11:25:31
NME

Base Information

Drug NameDeuterated nintedanib
Drug Alias NameSKLB-C-2202SKLB-C2202
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Deuterated drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsFibroblast growth factor receptor 1 antagonistsPlatelet-derived growth factor receptor alpha inhibitors
TargetsVascular endothelial growth factor receptor 2Fibroblast growth factor receptor 1Platelet-derived growth factor receptor alpha
Therapy Area/IndicationsIdiopathic Pulmonary FibrosisCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesHinova Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWest China Hospital Of Sichuan UniversityHinova Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsIdiopathic Pulmonary FibrosisCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A